Clinical Trials Browser

Interventional × Hodgkin Disease × ibrutinib × Clear all

Hodgkin Disease

NCT02824029 2025-02-17

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 2 Completed

28 enrolled 11 charts

Lymphoid

Hodgkin Disease

NCT02733042 2023-11-18

FUSION NHL 001

Phase 1/2 Completed

106 enrolled 48 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02869633 2023-10-23

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Phase 2 Completed

23 enrolled 10 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02626884 2021-04-08

IRENO

Phase 2 Completed

14 enrolled

Lymphoid

Hodgkin Disease

Clinical Trials

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

FUSION NHL 001

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

IRENO